Just sold my shares in Merant. (I know there is probably a few pence more in it. BUT, BUT BUT!!!!


Bought with it some more Bespac. I think it should go on the following information#, but spread is large.

2004 2005
Broker Date Rec Pre-tax ( ) EPS ( p ) DPS ( p ) Pre-tax ( ) EPS( p ) DPS( p )
Investec Securities 27 - 01 - 04 BUY 10.22 26.70 19.10 10.95 28.61 19.10
Seymour Pierce Ltd 01 - 03 - 04 OVAL 7.10 18.60 19.10 10.20 26.60 19.10
Numis Securities Ltd 26 - 02 - 04 BUY 12.00 32.80 15.00 40.00
Nomura Research Institute 02 - 02 - 04 BUY 13.00 35.50 19.10 23.00 62.80 19.10
Dryden Wealth Management Ltd 20 - 01 - 04 HOLD

Strong Buy Buy Weak Buy Weak Buy/Hold Hold Weak Sell/Hold Weak Sell Sell Strong Sell
0 3 0 0 1 0 0 0 1





RPT Bespak drug-delivery deal nears European approval, shares rise (Repeating to clarify nature of deal, adds share price other background) LONDON (AFX) - Bespak PLC said the European Medicines Evaluation Agency had accepted a filing by Pfizer Inc and Aventis SA who are both seeking rights to market Exubera, a diabetes treatment which is inhaled in powdered form. Bespak said it will manufacture the drug delivery device under an arrangement with Nektar Therapeutics, Inc, a US company which developed both Exubera and the means of delivering it. In a statement, Bespak said the timing of full scale production is as yet unknown and will depend in part on the speed of the regulatory review process. Pfizer and Aventis are seeking approval to market Exubera to adult patients with Type 1 and Type 2 diabetes. At 8.20 am Bespak was among the best performing small-cap stocks in the London market, gaining 22-1/2 pence, or 4.2 pct, to 557-1/2.

When they all said this was down and out I said buy at 523P on USA potential.

GO YOU LITTLE DARLIN'